GleamWall
中文EN

BIVI BIOVIE INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1580149 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-22.3%
TTM EPS YoY54.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-143.7%
ROA-119.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets40.9%
Debt / equity0.00x
Current ratio2.40x
Interest coverage-1,363.57x

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-19.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30
Income statement
Revenue——
R&D expense$13.96M$9.27M
SG&A expense$8.51M$8.57M
Operating income-$22.65M-$18.07M
Interest expense$17,901$332,720
Net income-$22.07M-$17.54M
EPS (basic)-3.05-12.12
EPS (diluted)-3.05-12.12
Weighted avg. shares (diluted)7.25M1.48M
Balance sheet
Cash & equivalents$8.98M$17.54M
Current assets$13.64M$20.70M
Goodwill$345,711$345,711
Intangibles—$178,341
Total assets$14.25M$21.56M
Current liabilities$3.80M$2.27M
Total liabilities$3.98M$2.55M
Shareholders' equity$10.27M$19.01M
Shares outstanding7.54M1.91M
Cash flow statement
Operating cash flow-$19.02M-$19.03M
Financing cash flow$10.46M$12.73M
Stock-based compensation$2.28M$1.20M

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.